Published in Bone on September 01, 1999
Osteoporosis: now and the future. Lancet (2011) 5.81
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest (2000) 5.78
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest (2005) 3.56
Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest (2006) 3.45
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
The gut microbiota regulates bone mass in mice. J Bone Miner Res (2012) 2.92
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest (2000) 2.32
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med (2002) 2.04
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut (2005) 1.91
Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr (2010) 1.87
Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest (2003) 1.65
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.64
Osteoporosis in inflammatory bowel disease. Am J Med (2009) 1.56
NF-Y is essential for the recruitment of RNA polymerase II and inducible transcription of several CCAAT box-containing genes. Mol Cell Biol (2005) 1.52
Osteoporosis, inflammation and ageing. Immun Ageing (2005) 1.40
Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis (2002) 1.35
Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci U S A (2007) 1.32
Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc Natl Acad Sci U S A (2007) 1.31
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29
Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis (2004) 1.25
HIV: inflammation and bone. Curr HIV/AIDS Rep (2012) 1.23
Interleukin-6 deficiency increases inflammatory bone destruction. Infect Immun (2001) 1.21
The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo) (2013) 1.20
High levels of tumor necrosis factor-alpha contribute to accelerated loss of cartilage in diabetic fracture healing. Am J Pathol (2009) 1.20
The immune system and bone. Arch Biochem Biophys (2010) 1.19
Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism. J Biol Chem (2008) 1.16
Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci Med Sci (2012) 1.12
Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest (2000) 1.09
Gamma interferon positively modulates Actinobacillus actinomycetemcomitans-specific RANKL+ CD4+ Th-cell-mediated alveolar bone destruction in vivo. Infect Immun (2005) 1.05
The role of T helper type 17 cells in inflammatory arthritis. Clin Exp Immunol (2009) 1.03
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther (2009) 1.02
Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors. Bone (2008) 1.02
The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. J Clin Immunol (2008) 0.99
The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2006) 0.98
Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. Proc Natl Acad Sci U S A (2000) 0.98
Bone loss. Factors that regulate osteoclast differentiation: an update. Arthritis Res (2000) 0.97
Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts. Biochem Med (Zagreb) (2013) 0.97
Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS One (2014) 0.97
Staphylococcus aureus induces expression of receptor activator of NF-kappaB ligand and prostaglandin E2 in infected murine osteoblasts. Infect Immun (2008) 0.96
Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts. J Cell Biochem (2009) 0.96
Associated bone mineral density and obstructive sleep apnea in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.94
Modulation of Wnt5a expression by periodontopathic bacteria. PLoS One (2012) 0.93
Bone remodelling markers in rheumatoid arthritis. Mediators Inflamm (2014) 0.92
Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells. Osteoporos Int (2011) 0.92
Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. Infect Immun (2003) 0.91
Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. J Clin Immunol (2004) 0.90
Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis (2007) 0.90
Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int (2010) 0.89
Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis. Arthritis Res (2001) 0.88
Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. J Bone Miner Metab (2007) 0.87
Prevention of bone growth defects, increased bone resorption and marrow adiposity with folinic acid in rats receiving long-term methotrexate. PLoS One (2012) 0.87
Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol (2012) 0.87
Effect of different localizations of microgap on clinical parameters and inflammatory cytokines in peri-implant crevicular fluid: a prospective comparative study. Clin Oral Investig (2011) 0.86
Inflammation, fracture and bone repair. Bone (2016) 0.85
Stimulation of osteoclast formation by inflammatory synovial fluid. Virchows Arch (2006) 0.85
Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia. Pediatr Surg Int (2009) 0.84
Activated γδ T cells inhibit osteoclast differentiation and resorptive activity in vitro. Clin Exp Immunol (2013) 0.83
Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition. PLoS One (2013) 0.83
Circulating monocytes: an appropriate model for bone-related study. Osteoporos Int (2015) 0.83
Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis. Int Orthop (2014) 0.82
Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget (2015) 0.82
t10c12-CLA maintains higher bone mineral density during aging by modulating osteoclastogenesis and bone marrow adiposity. J Cell Physiol (2011) 0.82
CXCL8 and CCL20 Enhance Osteoclastogenesis via Modulation of Cytokine Production by Human Primary Osteoblasts. PLoS One (2015) 0.81
Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World J Stem Cells (2014) 0.81
Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1. Clin Exp Immunol (2005) 0.81
Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Clin Rheumatol (2008) 0.81
Therapeutic potential of the proteasome inhibitor Bortezomib on titanium particle-induced inflammation in a murine model. Inflammation (2012) 0.81
Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol (2007) 0.81
A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse. J Bone Miner Res (2015) 0.80
Interleukin-1β, calcium-sensing receptor, and urokinase gene polymorphisms in korean patients with urolithiasis. Korean J Urol (2011) 0.79
Inhibitory effect of (-)-epigallocatechin gallate on titanium particle-induced TNF-α release and in vivo osteolysis. Exp Mol Med (2011) 0.79
Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study. BMC Nephrol (2012) 0.79
CD14 and TNFα single nucleotide polymorphisms are candidates for genetic biomarkers of peri-implantitis. Clin Oral Investig (2014) 0.78
Bone changes in alcoholic liver disease. World J Hepatol (2015) 0.78
Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo. Inflammation (2012) 0.78
Do γδ T cells predict osteonecrosis of the jaw? J Bone Miner Res (2013) 0.77
Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease. Dig Dis Sci (2001) 0.77
Regulation of bone lysis in inflammatory diseases. Inflammopharmacology (2003) 0.77
Density, structure, and strength of the distal radius in patients with psoriatic arthritis: the role of inflammation and cardiovascular risk factors. Osteoporos Int (2014) 0.77
Combination therapy with dexamethasone and osteoprotegerin protects against arthritis-induced bone alterations in antigen-induced arthritis of the rat. Inflamm Res (2010) 0.77
1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis. Biomed Res Int (2013) 0.77
Cross-talk between T cells and osteoclasts in bone resorption. Bonekey Rep (2012) 0.77
Peri-implant crestal bone loss: a putative mechanism. Int J Dent (2012) 0.77
Gene expression studies of osteoporosis: implications for microarray research. Osteoporos Int (2003) 0.77
Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. Clin Exp Immunol (2005) 0.77
Increased risk of incident osteoporosis and osteoporotic fracture in tuberculosis patients: a population-based study in a tuberculosis-endemic area. Osteoporos Int (2017) 0.77
A review of UHMWPE wear-induced osteolysis: the role for early detection of the immune response. Bone Res (2016) 0.76
The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis. Rheumatol Int (2010) 0.76
Soluble receptors for advanced glycation end products and receptor activator of NF-κB ligand serum levels as markers of premature labor. BMC Pregnancy Childbirth (2015) 0.76
Conjugated linoleic Acid prevents ovariectomy-induced bone loss in mice by modulating both osteoclastogenesis and osteoblastogenesis. Lipids (2013) 0.75
Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporos Int (2015) 0.75
Pasteurella multocida Toxin Triggers RANKL-Independent Osteoclastogenesis. Front Immunol (2017) 0.75
Growth factors and cytokines in patients with long bone fractures and associated spinal cord injury. J Orthop (2016) 0.75
Influence of Tumor Necrosis Factor α, Parathyroid Hormone, and Vitamin D3 on Modulation of the RANKL2 Isoform: A Pilot Study. Cartilage (2012) 0.75
Treatment of experimental periodontal disease by a selective inhibitor of cyclooxygenase-2 with scaling and root planing (SRP). Inflammopharmacology (2010) 0.75
Functional Local Renin-Angiotensin System in Human and Rat Periodontal Tissue. PLoS One (2015) 0.75
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Involutional osteoporosis. N Engl J Med (1986) 8.20
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Perspective. How many women have osteoporosis? J Bone Miner Res (1992) 4.99
The virtual hospital: a new paradigm for lifelong learning in radiology. Radiographics (1994) 4.64
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab (1998) 4.28
A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res (1998) 4.24
Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med (1992) 4.19
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
beta-Lactamase proceeds via an acyl-enzyme intermediate. Interaction of the Escherichia coli RTEM enzyme with cefoxitin. Biochemistry (1980) 3.94
Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. N Engl J Med (1982) 3.77
Weekend hospitalization and additional risk of death: an analysis of inpatient data. J R Soc Med (2012) 3.77
Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest (1981) 3.60
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
The networked multimedia textbook: distributing radiology multimedia information across the Internet. AJR Am J Roentgenol (1994) 3.35
Epidemiology of vertebral fractures in women. Am J Epidemiol (1989) 3.27
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 2.94
Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clin Orthop Relat Res (1981) 2.93
Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest (1982) 2.92
Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum (1984) 2.85
Evidence of estrogen receptors in normal human osteoblast-like cells. Science (1988) 2.85
Epidemiologic features of humeral fractures. Clin Orthop Relat Res (1982) 2.79
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int (2008) 2.74
Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int (2008) 2.72
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology (1999) 2.69
Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology (1999) 2.65
Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res (1993) 2.59
Murine homolog of SALL1 is essential for ureteric bud invasion in kidney development. Development (2001) 2.42
Secular trends in the incidence of hip fractures. Calcif Tissue Int (1987) 2.40
Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res (1990) 2.39
Osteoporosis and the risk of hip fracture. Am J Epidemiol (1986) 2.35
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology (1999) 2.27
Idiopathic osteoporosis--is the osteoblast to blame? J Clin Endocrinol Metab (1997) 2.25
Vertebral fractures predict subsequent fractures. Osteoporos Int (1999) 2.24
Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest (1979) 2.21
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
Evidence for two distinct syndromes of involutional osteoporosis. Am J Med (1983) 2.17
Incidence of Colles' fracture in a North American community. Am J Public Health (1982) 2.17
Isolation and characterization of osteoblast precursor cells from human bone marrow. J Bone Miner Res (1996) 2.16
Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders. Arthritis Rheum (1990) 2.03
Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause. J Clin Invest (1986) 2.01
Risk factors for spinal osteoporosis in men. Am J Med (1983) 2.00
Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res (2000) 1.98
Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res (1995) 1.97
Epidemiology of sarcopenia. J Am Geriatr Soc (2000) 1.97
Nonhistone chromosomal proteins and gene regulation. Science (1974) 1.92
Skeletal effects of estrogen. Endocr Rev (1994) 1.91
Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med (1984) 1.90
Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts. Nucleic Acids Res (1995) 1.89
Classification of vertebral fractures. J Bone Miner Res (1991) 1.89
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood (2001) 1.83
Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res (1998) 1.82
Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. J Clin Endocrinol Metab (1996) 1.79
Bone density and fracture risk in men. J Bone Miner Res (1998) 1.77
Progesterone-binding components of chick oviduct. 3. Chromatin acceptor sites. J Biol Chem (1971) 1.77
Comparison of sex steroid measurements in men by immunoassay versus mass spectroscopy and relationships with cortical and trabecular volumetric bone mineral density. Osteoporos Int (2008) 1.73
Prevalence and incidence of vertebral deformities. Osteoporos Int (1993) 1.72
Assessing forearm fracture risk in postmenopausal women. Osteoporos Int (2009) 1.71
Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest (1983) 1.69
Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer. J Clin Invest (1971) 1.68
Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. J Clin Invest (1997) 1.67
Genomic imprinting in mammals: an interplay between chromatin and DNA methylation? Trends Genet (1999) 1.67
Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart (2005) 1.65
Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci U S A (1991) 1.65